Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
22 studies found for:    " April 25, 2012":" May 25, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" April 25, 2012":" May 25, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression
Condition: Human Immunodeficiency Virus
Intervention: Drug: Atazanavir, ritonavir, lamivudine
2 Unknown  A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV
Condition: HIV Dementia
Interventions: Drug: Long acting methylphenidate;   Drug: Matched placebo
3 Recruiting Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer
Conditions: Cervical Cancer;   Acquired Immunodeficiency Syndrome
Interventions: Drug: cisplatin;   Radiation: external beam radiation therapy
4 Recruiting Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)
Condition: HIV Dementia
Interventions: Drug: Atorvastatin (generic Lipitor);   Drug: placebo
5 Completed A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 Oral;   Drug: GSK1265744 LAP 800mg intramuscular injection;   Drug: GSK1265744 LAP 200mg subcutaneous injection;   Drug: GSK1265744 LAP 200mg intramuscular injection;   Drug: GSK1265744 LAP 400mg intramuscular injection;   Drug: TMC278 LA 1200mg intramuscular injection;   Drug: TMC278 LA 600mg intramuscular injection
6 Completed A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: Maraviroc;   Drug: Combivir;   Drug: GSK2838510
7 Recruiting Alcohol's Impact on Inflammatory Markers in HIV Disease - Russia ARCH Cohort
Conditions: HIV Infection;   Alcohol Use
Intervention:
8 Completed Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir Monotherapy
Condition: HIV-infection
Intervention: Drug: Darunavir/ritonavir
9 Active, not recruiting A Mixed-Methods Approach to Understanding Factors Associated With Cervical Cancer Screening Utilization Among Low-Income, HIV-Positive Women
Conditions: Cancer Prevention;   Cervix
Interventions: Behavioral: Cognitive Interview;   Behavioral: Questionnaires;   Behavioral: Focus Groups
10 Recruiting Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV
Conditions: HIV Infection;   Tuberculosis
Interventions: Drug: Lopinavir/Ritonavir;   Drug: Raltegravir;   Drug: Isoniazid;   Drug: Pyridoxine;   Drug: Pyrazinamide;   Drug: Ethambutol;   Drug: Rifabutin;   Drug: Rifampin
11 Withdrawn Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir
Condition: HIV
Intervention:
12 Active, not recruiting Effects of a Protein Calorie Supplement in HIV-infected Women With Tuberculosis
Conditions: HIV;   Tuberculosis
Interventions: Dietary Supplement: Protein calorie supplement;   Dietary Supplement: Micronutrient
13 Active, not recruiting Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)
Conditions: HIV;   Osteoporosis
Intervention:
14 Recruiting Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV
Condition: HIV/AIDS
Interventions: Behavioral: BCAP peer-driven intervention (PDI);   Behavioral: Control intervention
15 Recruiting Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients
Condition: HIV-2 Infection
Intervention: Drug: emtricitabine / tenofovir disoproxil fumarate / raltegravir .
16 Completed Enhancing HIV Risk Reduction Among Indian Women With Risky Husbands
Condition: Behavioral Risk for HIV
Intervention: Behavioral: RHANI WIves
17 Recruiting The Health Access and Recovery Peer Program
Conditions: Hypertension;   Arthritis;   Coronary Artery Disease;   Hepatitis;   Diabetes;   Asthma;   Hyperlipidemia;   HIV
Intervention: Behavioral: HARP Intervention
18 Withdrawn Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
Condition: HIV
Interventions: Drug: Atazanavir;   Drug: Darunavir;   Drug: Ritonavir;   Drug: Optimized NRTI backbone
19 Active, not recruiting Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Conditions: Diabetic Retinopathy;   HIV
Interventions: Drug: Tesamorelin;   Drug: Placebo-Control
20 Unknown  Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy
Condition: HiV1- Positive
Intervention: Drug: Abacavir/Lamivudine

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years